Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial.
M. Boccadoro
Consultant or Advisory Role - Celgene
Research Funding - Celgene
F. Cavallo
Honoraria - Celgene
A. Nagler
No relevant relationships to disclose
D. Ben Yehuda
No relevant relationships to disclose
P. Omedè
No relevant relationships to disclose
M. Cavalli
No relevant relationships to disclose
A. Levi
No relevant relationships to disclose
C. Crippa
No relevant relationships to disclose
A. Siniscalchi
No relevant relationships to disclose
P. Brasca
No relevant relationships to disclose
A. M. Carella
No relevant relationships to disclose
B. A. Zanetti
No relevant relationships to disclose
F. Patriarca
Honoraria - Celgene
S. Pezzati
No relevant relationships to disclose
V. Montefusco
No relevant relationships to disclose
A. Stanevsky
No relevant relationships to disclose
B. Lupo
No relevant relationships to disclose
T. Caravita
Consultant or Advisory Role - Celgene
Honoraria - Celgene
F. Di Raimondo
Honoraria - Celgene
A. P. Palumbo
Consultant or Advisory Role - Celgene
Honoraria - Celgene